Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.62 |
| ▸ | DRD3 | P35462 | 3/20 | 0.62 |
| ▸ | DRD4 | P21917 | 8/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14372241 | 0.88 | DRD2 (0.62) | DRD2DRD3DRD4ALDH1A1SLC6A4 | |
| SCHEMBL5470063 | 0.84 | MAPT (0.59) | DRD2DRD3MAPTALDH1A1LMNA | |
| SCHEMBL5468391 | 0.82 | DRD2 (0.56) | DRD2DRD3DRD4MAPTALDH1A1 | |
| SCHEMBL5457584 | 0.82 | DRD2 (0.66) | DRD2DRD3DRD4SLC6A4 | |
| SCHEMBL14372243 | 0.82 | DRD3 (0.57) | DRD2DRD3DRD4HRH3SLC6A4 | |
| SCHEMBL6704588 | 0.81 | CHRM4 (0.62) | MAPTALDH1A1LMNAHPGDAKR1C3 | |
| SCHEMBL5464296 | 0.80 | DRD2 (0.62) | DRD2DRD3 | |
| SCHEMBL10401593 | 0.80 | DRD2 (0.72) | DRD2DRD3HRH3MAPTALDH1A1 | |
| SCHEMBL10401903 | 0.80 | DRD2 (0.72) | DRD2DRD3HRH3MAPTALDH1A1 | |
| SCHEMBL5476243 | 0.79 | DRD3 (0.61) | DRD2DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | DRD2 34/4885DRD3 78/4885DRD4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.